- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02827955
Evaluation of Bilateral Gamma Knife Thalamotomy in Patients Presenting With Severe Essential Tremor (VIMBIL)
Essential tremor (ET) is the most frequent movement disorder. Its prevalence is about 1/200 implying that at least 300 000 peoples are concerned in France. Its frequency increase with age (14% of patients 65 yo). The diagnostic criteria are postural and kinetic tremor that can be associated with head/voice tremor. ET induces a social impairment but also difficulties to perform any task requiring dexterity. With time, tremor can be so severe that every activity of daily living is impaired with loss of autonomy.
Treatment such as betablockers, primidone or antiepileptics might have some efficacy at the beginning. But as the severity of the tremor increases, there is lack of efficacy. Deep Brain stimulation (DBS) of the ventral intermediate nucleus (VIM) of the thalamus can be proposed. However, in case of medical or surgical contra-indication, Gamma Knife (GK) radiosurgery thalamotomy can be an alternative option.
Patients will be included with a minimum of 12 months after having the first thalamotomy (Gamma Knife 1) (done on the most annoying side) subject to no significant deterioration in cognitive assessment, voice assessment and balance and postural assessment or neuroradiological abnormality.
Patients will be assessed with Magnetic resonance imaging (MRI) cerebral, clinical assessment (tremor rating scale) impairment of activity of daily living, neuropsychological evaluation, voice assessment and balance and postural assessment.
The second thalamotomy (Gamma Knife 2) will be proposed and a monitoring at M6 and M12 will be done.
This study will demonstrate the feasibility and tolerance of bilateral GK radiosurgery thalamotomy in ET patients with severe impairment.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jean REGIS, PUPH
- Phone Number: 0691387058
- Email: jregis@ap-hm.fr
Study Locations
-
-
-
Marseille, France, 13354
- Assistance Publique Hopitaux de Marseille
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with essential tremor defined criteria Consensus statement of the movement Disorder Society on Classical Essential Tremor (1998), with trembling of the upper limbs causing functional impairment justifying surgical therapy.
- Man or woman aged 20 to 85 years.
- Patient having an absolute contraindication against or on Deep Brain Stimulation (DBS) of the VIM.
- Patient who received a first effective unilateral thalamotomy on tremor with a satisfactory clinical outcome (no cognitive impairment, lack of postural disorder Musculoskeletal severe lack of dysarthria). The first effective thalamotomy will be characterized by an improved score of tremor ≥ 45% and improved functional gene ≥ 50%.
- Patient who received a first unilateral thalamotomy with satisfactory radiological evolution. Unsatisfactory radiological evolution will be characterized by a contrast uptake> 350 mm3 one year with edema on T2 and Flair sequences extended beyond the internal capsule.
- Patient requiring contralateral treatment because of the severity of the tremor and functional impairment.
- Patient affiliated to a social protection scheme.
- Patient who understood and signed the informed consent form (signature of a third person possible when the patient is unable to read and / or write but in a state to give consent).
Exclusion Criteria:
- Patient with against-indication for performing a brain MRI (pacemaker, intracranial metallic objects etc.)
- Patient with an against-indication to radiosurgical treatment (prior treatment with cerebral radiotherapy)
- Pregnant or lactating women
Women of childbearing potential unless
- surgical sterilization
- use of effective contraception (intrauterine device or method more hormonal barrier method), and requiring to present a test pregnancy by assaying the negative serum with chorionic gonadotrope hormon (CGH) when selecting and accept to remain under the current form of contraception for the duration of the study (in women past menopause should be amenorrheic for at least 12 months to be considered as no longer able to bear a child).
- simultaneous participation in another clinical trial or exclusion period of a previous clinical trial.
- vulnerable persons: minors, protected adults (guardianship) and Major unable to consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: bilateral thalamotomy radiosurgery
Gamma Knife radiosurgery bilateral
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
evaluation of cognitive tolerance
Time Frame: 36 months
|
Define therapeutic technique "acceptable" in cognitive tolerance level by the Mini Mental State scale (MMS), 10% of subjects decrease their MMS over 2 points.
|
36 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jean REGIS, PUPH, Assistance Publique Hopitaux de Marseille
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013-38 (Other Identifier: APHM)
- 2013-A01289-36 (Other Identifier: IDRCB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Patients With Parkinson's Disease
-
University Hospital, RouenRecruitingPatients With Parkinson's Disease Treated With Apomorphine PumpsFrance
-
University Hospital, RouenNot yet recruiting
-
University Hospital, Clermont-FerrandUniversity Hospital, Rouen; Centre Hospitalier Universitaire de Saint Etienne; H. Lundbeck A... and other collaboratorsUnknownApathy | Drug-naïve Patients With Parkinson's DiseaseFrance
-
Meir Medical CenterUnknownPatients With Normal ECG | Patients With Pathological ECGIsrael
-
Greater Baltimore Medical CenterWithdrawnCancer | Patients With Clinical and Environmental Risk Factors for Cancer | Patients With a Suspected or Confirmed Diagnosis of CancerUnited States
-
University of Texas Southwestern Medical CenterWithdrawnPatients With a Diagnosis of Odynophonia
-
Centre Hospitalier Universitaire DijonCompletedPatients Undergoing Cardiac Surgery | Patients With Coronary Artery Bypass Surgery With CECFrance
-
National Taiwan University HospitalCompletedPostural and Suprapostural Performance During Dual Tasking in Patients With Parkinson's DiseaseTaiwan
-
Yonsei UniversityCompletedLevodopa Induced Dyskinesia in Patients With Parkinson's DiseaseKorea, Republic of
-
Rennes University HospitalTerminated
Clinical Trials on Gamma Knife® radiosurgery bilateral
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Swedish Medical CenterActive, not recruiting
-
Haukeland University HospitalCompleted
-
Yale UniversityTerminatedMelanoma | Sarcoma | Renal Cell Carcinoma | Breast Cancer | Colorectal Cancer | Lung Cancer | Brain Metastases | Gastrointestinal CancersUnited States
-
Assistance Publique Hopitaux De MarseilleUnknown
-
CancerCare ManitobaHealth Sciences Centre Foundation, ManitobaTerminatedNeoplasm MetastasesCanada
-
Elisabeth-TweeSteden ZiekenhuisZonMw: The Netherlands Organisation for Health Research and Development; Tilburg...CompletedNeoplasm MetastasesNetherlands
-
University of California, San FranciscoTerminated
-
Northwell HealthWithdrawnGlioblastoma | Malignant Glioma | Astrocytoma, Grade III | Astrocytoma, Grade IVUnited States
-
The Cooper Health SystemWithdrawnMetastatic Cancer | Brain MetastasesUnited States